We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
Read MoreHide Full Article
Key Takeaways
Amarin shares surged 17% after Q4 and FY2025 preliminary revenues came in above consensus expectations.
AMRN delivered positive Q4 cash flow earlier than planned on lower operating costs.
AMRN ended 2025 with $303M in cash, no debt, and an expanded global reach through Recordati-led partnerships.
Amarin’s (AMRN - Free Report) shares surged nearly 17% following the release of preliminary sales numbers for fourth-quarter and full-year 2025, which exceeded expectations.
Amarin’s top line currently comprises product revenues from Vascepa/Vazkepa (Vascepa’s brand name in Europe), complemented by licensing and royalty revenues.
Vascepa (icosapent ethyl) is approved as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride (TG) levels (≥500 mg/dL). It is also approved to reduce cardiovascular risk (CV) in patients with persistently elevated triglycerides on statin therapy for LDL-C.
Q4 & FY2025 Preliminary Results
Amarin expects preliminary total revenues for the fourth quarter to be in the range of $48 million to $53 million. The preliminary sales came in higher than the Zacks Consensus Estimate of $43 million.
For full-year 2025, preliminary total revenues are expected to be between $212 million and $217 million, above the Zacks Consensus Estimate of $207 million.
Restructuring costs are expected to range from $37-$40 million for full-year 2025, up from the prior estimate of $30-$37 million.
Amarin has already achieved approximately 50% of its planned $70 million operating expense reductions, with a plan to realize the full benefits by June 2026, supporting a lower operating cost structure and sustainable profitability.
The company achieved positive cash flow in the fourth quarter of 2025, which was earlier than its prior expectation of 2026. This may have also contributed to the stock’s rise on Thursday.
Amarin ended 2025 with approximately $303 million in cash and investments, up from $287 million in the third quarter of 2025 and remained debt-free, which further reduces the company’s financial risk.
Over the past year, shares of Amarin have risen 48.6% compared with the industry’s 19.2% growth.
Image Source: Zacks Investment Research
2026 Outlook
In June, Amarin signed an exclusive long-term license and supply agreement with Italy-based pharma company, Recordati, to commercialize Vazkepa in 59 countries, mainly across the European Union. The company has signed partnership deals with seven experienced partners providing access to nearly 100 markets. Per management, the fully partnered ex-U.S. business model should help reduce costs and achieve positive annual cash flow in 2026.
Vascepa/Vazkepa is approved in over 50 countries and protected by patents in Europe until 2039.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 58.3% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average surprise being 20.21%.
Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have declined 32.9% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 199.6% over the past year.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
Key Takeaways
Amarin’s (AMRN - Free Report) shares surged nearly 17% following the release of preliminary sales numbers for fourth-quarter and full-year 2025, which exceeded expectations.
Amarin’s top line currently comprises product revenues from Vascepa/Vazkepa (Vascepa’s brand name in Europe), complemented by licensing and royalty revenues.
Vascepa (icosapent ethyl) is approved as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride (TG) levels (≥500 mg/dL). It is also approved to reduce cardiovascular risk (CV) in patients with persistently elevated triglycerides on statin therapy for LDL-C.
Q4 & FY2025 Preliminary Results
Amarin expects preliminary total revenues for the fourth quarter to be in the range of $48 million to $53 million. The preliminary sales came in higher than the Zacks Consensus Estimate of $43 million.
For full-year 2025, preliminary total revenues are expected to be between $212 million and $217 million, above the Zacks Consensus Estimate of $207 million.
Restructuring costs are expected to range from $37-$40 million for full-year 2025, up from the prior estimate of $30-$37 million.
Amarin has already achieved approximately 50% of its planned $70 million operating expense reductions, with a plan to realize the full benefits by June 2026, supporting a lower operating cost structure and sustainable profitability.
The company achieved positive cash flow in the fourth quarter of 2025, which was earlier than its prior expectation of 2026. This may have also contributed to the stock’s rise on Thursday.
Amarin ended 2025 with approximately $303 million in cash and investments, up from $287 million in the third quarter of 2025 and remained debt-free, which further reduces the company’s financial risk.
Over the past year, shares of Amarin have risen 48.6% compared with the industry’s 19.2% growth.
Image Source: Zacks Investment Research
2026 Outlook
In June, Amarin signed an exclusive long-term license and supply agreement with Italy-based pharma company, Recordati, to commercialize Vazkepa in 59 countries, mainly across the European Union. The company has signed partnership deals with seven experienced partners providing access to nearly 100 markets. Per management, the fully partnered ex-U.S. business model should help reduce costs and achieve positive annual cash flow in 2026.
Vascepa/Vazkepa is approved in over 50 countries and protected by patents in Europe until 2039.
Amarin’s Zacks Rank & Stocks to Consider
AMRN currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Amicus Therapeutics (FOLD - Free Report) , CorMedix (CRMD - Free Report) and Indivior (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 58.3% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average surprise being 20.21%.
Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have declined 32.9% over the past year.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 199.6% over the past year.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.